



## Tuesday September 20 and Wednesday September 21 International program

### • Tuesday September 20

8:15 - 9:00 Welcome and registration of the participants

9:00 - 9:15 Introduction to the 2011 Forum by Hervé WATIER and Jean-Yves BONNEFOY

**9:15 - 12:15 Session « Antibody selection »** - Chairmen: Franck PEREZ, Philippe MONDON

9:15 - 10:00 Andrew GRIFFITHS *Institut de science et d'ingénierie supramoléculaires (ISIS), Strasbourg*  
Comparing tools for antibody screening

10:00 - 10:30 Pierre MARTINEAU *Institut de recherche en cancérologie de Montpellier (IRCM), Montpellier*  
Tailoring antibody libraries for diversity, expression and affinity

*10:30 - 11:00 : Coffee break*

11:00 - 11:45 André TRAUNECKER *Novartis Pharma, Basel, Switzerland*  
NIBR mouse - A personal journey from magic bullet to therapeutic magic bullet

11:45 - 12:15 Michel COGNÉ *Physiologie moléculaire de la réponse immune et des lymphoproliférations, Limoges*  
*In vitro* and *in vivo* evaluation of anti-CD20 chimeric antibodies shows the IgA-class to surpass IgG for direct effect on target cells

*12:15 - 14:00 : Lunch*

**14:00 - 18:15 Session « Antibody engineering and preclinical assessment » - Part 1**

Chairmen : Philippe ANCIAN, André PELEGRIN

14:00 - 14:45 Stefan DÜBEL *University of Braunschweig, Germany*  
Improved recombinant antibodies for research, diagnostics and therapy

14:45 - 15:30 Frédéric DUCANCEL *Institut de biologie et de technologies de Saclay, CEA, Gif-sur-Yvette*  
Antibody engineering for therapy and imaging

*15:30 - 15:45 : Coffee break*

15:45 - 16:30 Alain BECK *Centre d'immunologie Pierre Fabre (CIPF), Saint-Julien en Genevois*  
Therapeutic antibodies structural characterization and optimization

16:30 - 17:15 Jean-Luc TEILLAUD *Biotechnologie des anticorps, Centre de recherche des Cordeliers, Paris*  
Long-lasting antitumor protection by anti-CD20 antibody through cellular adaptive immune response

17:15 - 17:35 Hélène HAEGEL *Transgene, Illkirch*  
Development of an antibody with multiple intervention points for cancer therapy

17:35 - 17:55 Mireia PELEGRIN *Institut de génétique moléculaire, Montpellier*  
Vaccine-like effects of neutralizing monoclonal antibodies: a crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy

17:55 - 18:25 Philippe THUILLIER *Unité de biotechnologie des anticorps et des toxines, CRSSA-IRBA, La Tronche*  
Germline-humanization: toward the fourth generation of recombinant antibodies

18:25 - 19:30 Poster session (*Refreshments*)

19:30 - 20:15 Introduction of the guest speaker by Étienne WEISS

Marc VAN REGENMORTEL *Biotechnologie et signalisation cellulaire, Illkirch*  
Antigens, immunogens and HIV-1 vaccine design

*20:15 : Gala dinner*

# ACCITH 2011 Scientific program

## • Wednesday September 21

### 9:00 - 9:45 Session « Antibody engineering and preclinical assessment » - Part 2

Chairpersons: Martine CERUTTI, Thierry WURCH

- 9:00 - 9:15 Naima ABIDI-AZZOUZ *Centre de recherches de biochimie macromoléculaire, Montpellier*  
Nanobodies based on a dromedary single-domain antibody targeting the reverse transcriptase of HIV-1
- 9:15 - 9:30 Marie VINCENT *Centre de recherche en cancérologie, Nantes*  
Development of two IL15 immunocytokines targeting either GD2- or CD20- tumoral bearing cells
- 9:30 - 9:45 Patricia ROUSSELLE *Institut de biologie et chimie des protéines, Lyon*  
Adhesio-mAb: a anti-laminin monoclonal antibody for cancer therapy

### 9:45 - 13:15 Session « Antibody bioproduction »

Chairpersons: Martine CERUTTI, Thierry WURCH

- 9:45 - 10:30 Yannick SORLET *Novartis Pharma, Huningue*  
Insights and challenges related to a large scale, multipurpose mAb manufacturing facility
- 10:30 - 11:15 Roland BELIARD *Laboratoire Français Fractionnement Biotechnologies (LFB), Paris*  
Challenges and issues in the development of biologicals: from the lead molecule to the marketed product

*11:15 - 11:45 : Coffee break*

- 11:45 - 12:30 Ralf RESKI *Université de Fribourg, Allemagne*  
Antibody production in moss bioreactors
- 12:30 - 13:15 Concluding remarks  
Sylviane MULLER (*UPR 9021, Strasbourg*) and Hervé WATIER, *Chairman of the ACCITH group*